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Lymphangiogenesis, the formation of new lymph vessels, plays a signiﬁcant role in the development and
metastasis of various cancers. We and others have demonstrated that low molecular weight hyaluronan
(LMW-HA) promotes lymphangiogenesis. However, the underlying mechanisms are poorly deﬁned. In
this study, using immunoﬂuorescence and co-immunoprecipitation, we found that LMW-HA increased
the colocalization of lymphatic vessel endothelial HA receptor (LYVE-1) and sphingosine 1-phosphate
receptor (S1P3) at the cell surface. Silencing of either LYVE-1 or S1P3 decreased LMW-HA-mediated tube
formation in lymphatic endothelial cells (LECs). Furthermore, silencing of either LYVE-1 or S1P3 sig-
niﬁcantly inhibited LMW-HA-induced tyrosine phosphorylation of Src kinase and extracellular signal-
regulated kinase (ERK1/2). In summary, these results suggest that S1P3 and LYVE-1 may cooperate to
play a role in LMW-HA-mediated lymphangiogenesis. This interaction may provide a useful target for the
intervention of lymphangiogenesis-associated tumor progression.
& 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Lymphangiogenesis, the generation of new lymphatic vessels, is
considered an important step in cancer dissemination and me-
tastasis [1,2]. This process involves extracellular interactions be-
tween the inner endothelial layer and the surrounding matrix.
Clinical and experimental evidence suggest that lymphangiogen-
esis is associated with poor prognosis in cancer patients [3]. Un-
derstanding the molecular mechanisms that regulate lym-
phangiogenesis could have a signiﬁcant impact on the develop-
ment of novel treatment strategies.
Hyaluronan (HA) is a linear polymer that belongs to the gly-
cosaminoglycan (GAG) family, which comprises the major fraction
of carbohydrates in the extracellular matrix (ECM) [4]. Studies on
histological sections from various types of tumors revealed that
tumor ECM is rich in HA. Ectopic expression of HA is associated
with cancer malignancy and aggressiveness in breast, stomach andInc. This is an open access article u
lar Biology and Clinical La-
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.colon carcinomas [5]. HA molecules have a large variability in
length and can reach up to 107 Da in size. The molecular weight of
HA can affect its biological characteristics. High molecular weight
HA (HMW-HA) exerts anti-angiogenic and immunosuppressive
effects. By contrast, low molecular weight HA (LMW-HA), which is
synthesized or generated by either hyaluronidase-mediated de-
gradation or hydrolysis of native HA under pathological condi-
tions, plays a more active biological role and is involved in cell
growth, angiogenesis and migration [6,7]. Recently, increasing
evidence has shown that LMW-HA plays a signiﬁcant role in
lymphangiogenesis [8,9]; however, the precise molecular me-
chanism remains unclear. Therefore, it is of great signiﬁcance to
explore the exact molecular mechanism underlying LMW-HA-
mediated lymphangiogenesis.
Sphingosine 1-phosphate receptor (S1P3), formerly known as
endothelial differentiation gene-3 (Edg-3), regulates endothelial
cell functions, such as angiogenesis and barrier function [10].
S1P3-mediated activation of extracellular signal-regulated kinase
(ERK1/2) is involved in S1P3 ligand-induced angiogenesis [11–13].
As reported previously, the interaction between S1P3 and CD44
(vascular endothelial HA receptor) plays a role in LMW-HA-
mediated barrier disruption in vascular endothelial cells [14].
Moreover, the barrier function of vascular endothelial cells wasnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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covered homolog of the CD44 glycoprotein, has an overall
homology of 41% with CD44 and is largely restricted to the en-
dothelial cells that line lymphatic vessels as a lymph-speciﬁc re-
ceptor for HA [17]. This discovery raised the interesting possibility
that S1P3 may interact with LYVE-1 to play a role in LMW-HA-
mediated lymphangiogenesis.
In this study, we examined the different effects of HMW-HA
and LMW-HA on lymphangiogenesis, including the proliferation,
migration and tube formation of lymphatic endothelial cells
(LECs). To further clarify the mechanism underlying LMW-HA in-
duced lymphangiogenesis, we explored the association of S1P3
with LYVE-1 in LECs and silenced LYVE-1 and S1P3 to investigate
their roles in LMW-HA-induced LEC tube formation and inter-
cellular signaling transduction.2. Materials and methods
2.1. Antibodies and reagents
Rabbit polyclonal anti-LYVE-1 receptor was purchased from
Santa Cruz Biotechnology (Santa Cruz, CA, USA). Rabbit mono-
clonal anti-S1P3 receptor was purchased from Abcam (Cambridge,
MA, USA). Rabbit monoclonal anti-phospho-Src and anti-phospho-
ERK1/2 (Tyr202/Tyr204) were obtained from Cell Signaling Tech-
nology (Beverly, MA, USA). Native HMW-HA was obtained from
Sigma-Aldrich (St. Louis, MO). LMW-HAwas prepared as described
previously [16]. LMW-HA was prepared as a mixed fraction with
an average molecular weight of 2.5106 and was composed of 3–
10 disaccharide units that were fractionated from testicular hya-
luronidase type 1-S (Sigma-Aldrich) digests of hyaluronan sodium
salt (Sigma-Aldrich).
2.2. Cell cultures
The murine endothelial cell line SVEC4-10 (American Type
Culture Collection), which was recently characterized as lymphatic
endothelial cells [17], was cultured in Dulbecco's modiﬁed Eagle's
medium (DMEM, Gibco, Invitrogen) supplemented with 10% fetal
bovine serum (FBS) in a humid atmosphere at 37 °C under 5% CO2.
2.3. Cell proliferation assay
SVEC4-10 cells were seeded in 96-well plates at a density of
4103 cells/well and cultured in 100 mL of DMEM with 10% FBS
overnight at 37 °C under 5% CO2. After the medium was removed,
the cells were treated with DMEM plus 10 mg/ml HMW-HA, 10 mg/
ml LMW-HA, or medium only for 48 h at 37 °C under 5% CO2, then
20 ml methylthiazolyldiphenyl-tetrazolium bromide (MTT) reagent
was added to each well and the plates were incubated for 4 h at
37 °C. The absorbance was measured using a microplate reader
(Bio-Rad, Model 550) at a wavelength of 492 nm.
2.4. Transwell monolayer permeability assay
The migration activity of SVEC4-10 cells was evaluated using a
transwell system (Corning Costar, MA, USA) that was composed of
8 mm polycarbonate ﬁlter inserts in 24-well plates. Brieﬂy, serum-
starved cells were trypsin-harvested in DMEM. Then, 1104
SVEC4-10 cells were suspended in 200 mL of serum-free DMEM
and seeded in the upper chambers, and the lower chambers were
ﬁlled with 700 ml of DMEM with 10% FBS containing 10 mg/ml
HMW-HA, 10 mg/ml LMW-HA, or medium only. After incubation
for 24 h at 37 °C under 5% CO2, cells on the upper surface of the
ﬁlter were removed using a cotton swab and the membranebetween the two compartments was ﬁxed and stained with 1%
crystal violet. Cells on the lower surface of the ﬁlter were photo-
graphed using brightﬁeld optics with a 100 objective lens (Ni-
kon, Tokyo, Japan) and counted.
2.5. Tube formation assay
A matrigel-based tube formation assay was performed as pre-
viously described. Each well of a 96-well plate was coated with
100 ml of Matrigel (BD Biosciences, Bedford, MA, USA), which was
allowed to polymerize for 30 min at 37 °C. Serum-starved SVEC4-
10 cells (2104) were dispensed into each well in 100 mL of EBM-
2, with 10 mg/ml HMW-HA, 10 mg/ml LMW-HA, or medium only.
After incubation for 6 h at 37 °C under 5% CO2, images of the tube
formation were captured using microscopy, and the relative tube
length was calculated by normalizing the results to the control
group. Each treatment was performed in triplicate and experi-
ments were repeated three times. The results are expressed as the
relative tube length per treatment.
2.6. Immunoﬂuorescence staining
SVEC4-10 cells grown on coverslips for 2 days (50–60% con-
ﬂuence) were treated with 10 mg/ml HMW-HA, 10 mg/ml LMW-HA
or medium only for 30 min in serum-free DMEM. After treatment,
cells were washed with PBS twice and ﬁxed with methanol at
20 °C for 10 min. Then, cells were washed with PBS and blocked
with 1% bovine serum albumin in PBS at room temperature for 1 h.
Next, cells were incubated overnight with anti-LYVE-1 antibody
and anti-S1P3 antibody at 1:100 and 1:200 dilution, respectively.
After extensive washing, cells were incubated with Alexa Fluxo
488-conjugated donkey anti-rabbit IgG and Alexa Fluxo 594-con-
jugated donkey anti-goat IgG secondary antibodies at 1:100 dilu-
tion for 2 h at room temperature. Nuclei were stained with DAPI
for 10 min at room temperature. Images were acquired using a
confocal microscope (Nikon, Tokyo, Japan).
2.7. Immunoprecipitation and immunoblotting
Cells were lysed in buffer containing 20 mM Tris (pH 7.5),
150 mM NaCl, 1% NP40, 1 mM EDTA, 5 mM NaF and 5 mM Na3VO4.
The samples were then either immunoprecipitated with anti-
LYVE-1 or not immunoprecipitated followed by SDS-PAGE in 12%
polyacrylamide gels, transferred to nitrocellulose membranes, and
immunoblotted with speciﬁc primary and secondary antibodies.
Immunoreactive bands were developed using a chemilumines-
cence assay (Pierce) and visualized using Image pro-Plus
6.0 software.
2.8. Sirna transfection
Transfections of cells with S1P3, LYVE-1, and scramble siRNA
were performed according to the manufacturer's protocol (Santa
Cruz Biotechnology). Brieﬂy, SVEC4-10 cells were grown on six-
well tissue culture plates to 60–80% conﬂuence. Cells were then
washed twice with transfection medium (sc-36868). Aliquots of
0.2 ml of transfection medium containing scramble siRNA (sc-
37007), S1P3 siRNA (sc-35262), and LYVE-1 siRNA (sc-42902) and
8 mL of transfection reagent (sc-29528) were incubated at room
temperature for 30 min before being added to the cells. Cells were
used for experiments 48 h after transfection.
2.9. Statistical analysis
Analyses were performed using the statistical software
SPSS13.0. Differences were considered statistically signiﬁcant at
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for each assay.3. Results
3.1. LMW-HA increased LEC proliferation
LECs were treated with HMW-HA or LMW-HA at various con-
centrations, ranging from 0 to 40 mg/ml. The most signiﬁcant effect
of LMW-HA on proliferation occurred at 10 mg/ml, and there was
no signiﬁcant effect of HMW-HA on LEC proliferation compared
with control (Fig. 1).
3.2. LMW-HA promoted LEC migration
Based on the optimal concentration in promoting SVEC4-10
proliferation, 10 mg/ml LMW-HA was used for further experiments.
The number of migrated cells in groups treated with 10 mg/ml
LMW-HA was signiﬁcantly increased (Po0.01), but HMW-HA had
no signiﬁcant effect on cell migration (Fig. 2).
3.3. LMW-HA enhanced LEC tube formation
Tube formation of LECs was signiﬁcantly enhanced by 10 mg/ml
LMW-HA (Po0.01). This is consistent with previous reports [5]
that found LMW-HA could stimulate lymphangiogenesis. HMW-
HA did not exert signiﬁcant effects on tube formation (Fig. 3).
3.4. Effects of HMW-HA and LMW-HA on the phosphorylation of Src
kinase and ERK1/2 in LECs
Src kinase and its downstream molecular mediator ERK1/2 are
involved in regulating cell growth, differentiation, and migration
[18]. The phosphorylation of Src kinase and ERK1/2 is involved in
LMW-HA-induced angiogenesis [19]. To understand the in-
tracellular mechanism through which LMW-HA promoted lym-
phangiogenesis, we studied the effect of LMW-HA on the activa-
tion of Src kinase and ERK1/2 signaling in LECs. The results of
western blotting showed that LMW-HA induced the phosphor-
ylation of Src kinase and ERK1/2 in a time-dependent manner in
LECs. Typically, LMW-HA stimulated a strong and sustained
phosphorylation of both Src kinase and ERK1/2 with 30 min of
incubation in LECs. In the meanwhile, the expressions of total Src
kinase and ERK1/2 remained unaltered from 0 to 60 min (Fig. 4A).
We further analyzed the effects of HMW-HA and LMW-HA on
phosphorylation of Src kinase and ERK1/2 with 30 min of in-
cubation in LECs. We found that LMW-HA signiﬁcantly increasedFig. 1. Effects of HMW-HA and LMW-HA on LEC proliferation. SVEC4-10 cells were treat
and 5% CO2 in 96-well culture plates. Cell proliferation was examined using MTT assays.the protein levels of phosphorylated Src kinase and ERK1/2 com-
pared with control (Po0.01). In contrast, HMW-HA presented no
signiﬁcant effects on phosphorylation of Src kinase and ERK1/2
(Fig. 4B).
3.5. LMW-HA increased S1P3 and LYVE-1 colocalization in LECs
A previous study showed that LMW-HA interacted with CD44
to induce angiogenesis [20,21]. Moreover, LMW-HA induced an
association of S1P3 with CD44 in lipid raft microdomains [21].
Thus, we explored the effects of LMW-HA on the localization of
S1P3 and LYVE-1 in LECs. Using immunoﬂuorescence assays, we
showed that in the absence of treatment, LYVE-1 colocalized with
S1P3 on the cell membrane and in the cytoplasm (Fig. 5A–E).
Treatment with LMW-HA resulted in an increase in the colocali-
zation of LYVE-1 and S1P3 (Fig. 5A–O). Using co-im-
munoprecipitation, we found that the association between LYVE-1
and S1P3 was signiﬁcantly increased upon LMW-HA treatment,
whereas the association remained unchanged with HMW-HA
treatment (Fig. 5A).
3.6. Role of LYVE-1 and S1P3 in LMW-HA-induced
lymphangiogenesis
Previous studies have shown that the interaction of LMW-HA
and its receptor induces tube formation and tyrosine phosphor-
ylation of Src kinase and ERK1/2 in vascular endothelial cells [22].
Therefore, we hypothesized that LYVE-1 and S1P3 may have roles
in LMW-HA-induced tube formation and activation of Src kinase
and ERK1/2 signaling pathways. Using western blot analysis,
we found that treating LECs with either LYVE-1 or S1P3 siRNA
signiﬁcantly reduced the protein levels of LYVE-1 and S1P3, re-
spectively (Fig. 7A and C). Silencing of either LYVE-1 or S1P3 sig-
niﬁcantly inhibited LMW-HA-mediated LEC tube formation
(Fig. 6A) and the activation of Src kinase and ERK1/2 signaling
(Fig. 7B and D).4. Discussion
There is growing evidence that lymphangiogenesis is one of the
most important prognostic factors in various types of cancer [23].
Clinical evidence suggests that the dissemination of malignant
tumor cells to regional lymph nodes via lymphangiogenesis is
important in tumor metastasis; however, the molecular mechan-
isms regulating lymphangiogenesis are largely unclear [24].
Although previous studies have reported that VEGF-C and
PDGF-BB are the most potent lymphangiogenic growth factors,ed with 10, 20, and 40 mg/ml HMW-HA, LMW-HA or medium only for 48 h at 37 °C
Each assay was prepared in triplicate and repeated at least ﬁve times. (**Po0.01).
Fig. 2. LMW-HA stimulated LEC migration. SVEC4-10 cell migration was evaluated using transwell assays. Cells were seeded on the upper chambers, and medium containing
10 mg/ml HMW-HA, 10 mg/ml LMW-HA or medium only was added to the lower chambers. After 24 h of incubation, cells attached to the lower membrane were stained with
0.1% crystal violet (100 magniﬁcation). A, Representative photographs of SVEC4-10 migration (scale bar, 100 mm). B, The migrated cells in each ﬁeld were counted (100
magniﬁcation, 10 random ﬁelds). Each assay was prepared in triplicate and repeated at least ﬁve times. (**Po0.01).
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found in the extracellular matrix, could also promote lym-
phangiogenesis [25,26]. Under various pathologic conditions,
LMW-HA rapidly accumulates in the affected interstitial space andFig. 3. LMW-HA promoted tube formation of LECs. Tube formation assays were performe
of SVEC4-10 cell tube formation on Matrigel after 6 h of treatment with 10 mg/ml HMW
shown as pixel length per ﬁeld. Each treatment was performed in triplicate and experiappears to function as an endogenous “danger signal” related to
tumor metastasis [27–29]. LMW-HA-induced lymphangiogenesis
may be an important mechanism in tumor metastasis. Therefore,
knowledge of the molecular mechanisms underlying LMW-HA-d as described in the materials and methods section. A, Representative photographs
-HA or 10 mg/ml LMW-HA. B, The total tube formation length was measured and is
ments were repeated three times. (**Po0.01).
Fig. 4. Src kinase and ERK1/2 were activated following LMW-HA treatment of LECs. A, SVEC4-10 cells were stimulated with 10 mg/ml of LMW-HA from 0 to 60 min. Protein
samples were immunoblotted for total and phosphorylated Src kinase and ERK1/2. B, SVEC4-10 cells were stimulated with 10 mg/ml of HMW-HA or 10 mg/ml of LMW-HA for
30 min and phosphorylations of Src kinase and ERK1/2 were analyzed by western blotting. Relative densitometry was analyzed using Image Pro Plus 6.0 software. Data were
representative of three independent experiments. (**Po0.01).
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treatments for the modulation of lymphangiogenic diseases.
During lymphangiogenesis, the proliferation, migration and
tube formation of LECs are important processes that maintain the
net vascular structure by replenishing new endothelial cells in the
empty space [30]. In this study, we showed that 10 mg/ml of LMW-
HA induced LEC proliferation, migration and tube formation,
whereas HMW-HA at the same concentration had no signiﬁcant
effect on lymphangiogenesis (Figs. 1–3). Consistent with a pre-
vious report [6], our results suggest that LMW-HA can induce
lymphangiogenesis. To further explore the intracellular mechan-
ism underlying LMW-HA-mediated lymphangiogenesis, we de-
termined the effect of LMW-HA on the activation of Src kinase and
the ERK1/2 signal transduction pathway. Src kinase is a regulatory
protein that participates in cell differentiation, migration and
proliferation [31,32]. ERK1/2, a member of the mitogen-activated
protein kinase (MAPK) family, contributes to cell proliferation,
migration, differentiation and apoptosis [33]. Inhibition of Src ki-
nase and ERK1/2 can suppress lymphangiogenesis both in vitro
and in vivo [34,35]. A previous study reported that LMW-HA
promoted the phosphorylation of Src kinase and ERK1/2 and in-
creased the expression of cyclin D1, resulting in enhanced PIEC
proliferation [36]. Our results showed that LMW-HA signiﬁcantly
induced phosphorylation of Src kinase and its downstream signal
ERK1/2 (Fig. 4), which suggested that activation of Src kinase and
ERK1/2 may be involved in LMW-HA-induced lymphangiogenesis.
S1P3, a lipid-activated G protein-couple receptor, is expressed
in many cell types, including endothelial cells [37]. The S1P re-
ceptor was originally identiﬁed as an immediate early gene pro-
duct that was abundantly induced during the activation of en-
dothelial cells, suggesting that S1P3 may participate in the (patho)
physiological regulation of endothelial cell functions [38,39]. More-
over, S1P3 could play a vital role in processes that regulate ligand-mediated angiogenesis and endothelium permeability, including
cell–cell junction assembly, morphogenesis, cell survival, and vessel
formation [40–42]. It has been reported that S1P3 and CD44 colo-
calized and interacted in vascular endothelial cell lipid rafts and that
this interaction played an important role on LMW-HA induced bar-
rier regulation [15]. During vascular sprouting, junctions are partially
disorganized and barrier function is disrupted by increasing vascular
permeability, which allows endothelial cells to migrate, proliferate
and undergo angiogenesis [14]. LYVE-1, a major receptor for HA on
LECs, is a member of the Link protein superfamily and is similar to
CD44 with signiﬁcant sequence homology [43]. Based on the colo-
calization of S1P3 and CD44 in vascular endothelial cells and its role
in LMW-HA-mediated EC biology, it could be speculated that S1P3
may colocalize with LYVE-1 in LECs. Consistent with this hypothesis,
we determined using immunoﬂuorescence and coimmunoprecipi-
tation assays that native S1P3 and LYVE-1 colocalized with each
other. (Fig. 5A and B).
A previous study found that LYVE-1 played a signiﬁcant role in
LMW-HA-induced lymphangiogenesis [5]. Our results showed that
accompanying LMW-HA-induced lymphangiogenesis, LMW-HA
also induced an increase in the colocalization of S1P3 and LYVE-1
(Fig. 5A–O), raising the possibility that S1P3 may interact with
LYVE-1 and participate in LMW-HA-mediated lymphangiogenesis.
Further experiments showed that silencing either LYVE-1 or S1P3
signiﬁcantly inhibited LMW-HA-induced tube formation (Fig. 6). In
addition, when either LYVE-1 or S1P3 was silenced, the LMW-HA-
induced phosphorylation of Src kinase and ERK1/2 was sig-
niﬁcantly decreased (Fig. 7B and D). Overall, our results revealed
that S1P3 and LYVE-1 may cooperate to play an important role in
LMW-HA-induced lymphangiogenesis.
In conclusion, this study demonstrated for the ﬁrst time that
LMW-HA can increase the colocalization of LYVE-1 and S1P3 re-
ceptors in LECs. We also corroborated the crucial involvement of
Fig. 5. S1P3 and LYVE-1 colocalize following stimulation of LECs with HMW-HA and LMW-HA. A, Immunoﬂuorescence assays were performed as described in the materials
and methods section to determine the localization of LYVE-1 and S1P3 in SVEC4-10 cells. Cells were seeded on coverslips and treated with medium only (a–e), 10 mg/ml
HMW-HA (f–j) or 10 mg/ml LMW-HA (k–o) for 30 min. Cells were stained with anti-LYVE-1 antibody (a, f, and k), anti-S1P3 antibody (b, g, and l) and DAPI (e, h, and m) and
merged (d, i, and n). Images were taken at 60 magniﬁcation using confocal microscopy. The green and red labelingshow the localization of LYVE-1 and S1P3, respectively,
and yellow ﬂuorescence represents the colocalization of the two receptors in merged images. B, Co-immunoprecipitation assays were performed as described in the
materials and methods section. Proteins were immunoprecipitated with anti-LYVE-1 for co-IP assays. The data shown represent one of three independent experiments. (For
interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 6. Silencing of either LYVE-1 or S1P3 inhibited LMW-HA-induced tube formation. A, LYVE-1, S1P3 and scramble silenced SVEC4-10 cells were plated on Matrigel in the
presence or absence of 10 mg/ml HMW-HA or LMW-HA. Images were captured after 6 h of incubation as described previously. B, The total tube length was measured and is
shown as pixel length per ﬁeld; the asterisks indicate a statistically signiﬁcant difference compared with control (**Po0.01). Each treatment was performed in triplicate and
experiments were repeated three times.
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Fig. 7. Silencing of either LYVE-1 or S1P3 reduced LMW-HA-induced phosphorylation of Src kinase and ERK1/2. A and C, SVEC4-10 cells were pretreated with siRNA to
silence LYVE-1 or S1P3 for 48 h, then incubated with 10 mg/ml HMW-HA or 10 mg/ml LMW-HA for 30 min. B and D, The phosphorylation of Src kinase and ERK1/2 was
analyzed via Western blotting. The relative densitometry was analyzed using Image Pro Plus 6.0 software. The data shown represent one of three independent experiments.
(**Po0.01).
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activation of Src kinase and ERK1/2 signal transduction. The dis-
covery of the role of S1P3 and LYVE-1 in LMW-HA-mediated
lymphangiogenesis could lead to the development of improved
therapeutics in the treatment of lymphangiogenesis-associated
diseases, including tumor progression.Conﬂict of interest
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